



## King's Research Portal

DOI:

[10.1371/journal.pone.0142408](https://doi.org/10.1371/journal.pone.0142408)

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Daci, A., Beretta, G., Villasaliu, D., Shala, A., Govori, V., Norata, G. D., & Krasniqi, S. (2015). Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of kosovar albanian epileptic patients. *PLoS One*, 10(11), [0142408]. <https://doi.org/10.1371/journal.pone.0142408>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH ARTICLE

# Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients

Armond Daci<sup>1,2,6</sup>, Giangiaco Beretta<sup>3</sup>, Driton Vllasaliu<sup>4</sup>, Aida Shala<sup>1</sup>, Valbona Govori<sup>5</sup>, Giuseppe Danilo Norata<sup>6,7</sup>, Shaip Krasniqi<sup>2\*</sup>

**1** Department of Pharmacy, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo, **2** Institute of Pharmacology and Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo, **3** Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy, **4** University of Lincoln, School of Pharmacy, Joseph Banks Laboratories, Green Lane, Lincoln, LN6 7DL, United Kingdom, **5** Neurology Clinic, University Clinical Center of Kosova, Prishtina, Kosovo, **6** Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy, **7** Center for the Study of Atherosclerosis, Ospedale Bassini, Cinisello Balsamo, Italy

\* [shaip.krasniqi@uni-pr.edu](mailto:shaip.krasniqi@uni-pr.edu)



OPEN ACCESS

**Citation:** Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, et al. (2015) Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. PLoS ONE 10(11): e0142408. doi:10.1371/journal.pone.0142408

**Editor:** Olga Y Gorlova, Geisel School of Medicine at Dartmouth College, UNITED STATES

**Received:** June 5, 2015

**Accepted:** October 20, 2015

**Published:** November 10, 2015

**Copyright:** © 2015 Daci et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This project was supported by a grant from the Ministry of Education, Science and Technology of Kosovo (No 4409). AD and GB received two scholarships from SIGMA Project for academic exchange program founded by the European Commission (Critical Skills Learning for Innovation, Sustainable Growth Mobility and Employ Ability in the Multicultural Environment of the Western Balkans; contract numbers: SIGM1200261, SIGM1200277).

## Abstract

### Aim

The present study aimed to evaluate the effects of gene variants in key genes influencing pharmacokinetic and pharmacodynamic of carbamazepine (CBZ) on the response in patients with epilepsy.

### Materials & Methods

Five SNPs in two candidate genes influencing CBZ transport and metabolism, namely ABCB1 or EPHX1, and CBZ response SCN1A (sodium channel) were genotyped in 145 epileptic patients treated with CBZ as monotherapy and 100 age and sex matched healthy controls. Plasma concentrations of CBZ, carbamazepine-10,11-epoxide (CBZE) and carbamazepine-10,11-trans dihydrodiol (CBZD) were determined by HPLC-UV-DAD and adjusted for CBZ dosage/kg of body weight.

### Results

The presence of the SCN1A IVS5-91G>A variant allele is associated with increased epilepsy susceptibility. Furthermore, carriers of the SCN1A IVS5-91G>A variant or of EPHX1 c.337T>C variant presented significantly lower levels of plasma CBZ compared to carriers of the common alleles (0.71±0.28 vs 1.11±0.69 µg/mL per mg/Kg for SCN1A IVS5-91 AA vs GG and 0.76±0.16 vs 0.94±0.49 µg/mL per mg/Kg for EPHX1 c.337 CC vs TT; P<0.05 for both). Carriers of the EPHX1 c.416A>G showed a reduced microsomal epoxide hydrolase

Facilities and infrastructure were provided by Kosovo Interdisciplinary Knowledge Triangle Center (KIKTC, Tempus IV Grant). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have the following interests. This study was partly supported by the SIGMA which is a project for academic exchange program founded by the European Commission (Critical Skills Learning for Innovation, Sustainable Growth Mobility and Employ Ability in the Multicultural Environment of the Western Balkans; contract numbers: SIGM1200261, SIGM1200277). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

activity as reflected by a significantly decreased ratio of CBZD to CBZ ( $0.13 \pm 0.08$  to  $0.26 \pm 0.17$ ,  $p < 0.05$ ) also of CBZD to CBZE ( $1.74 \pm 1.06$  to  $3.08 \pm 2.90$ ;  $P < 0.05$ ) and  $CDR_{CBZD}$  ( $0.13 \pm 0.08$  vs  $0.24 \pm 0.19$   $\mu\text{g/mL per mg/Kg}$ ;  $P < 0.05$ ). ABCB1 3455C>T SNP and SCN1A 3148A>G variants were not associated with significant changes in CBZ pharmacokinetic. Patients resistant to CBZ treatment showed increased dosage of CBZ ( $657 \pm 285$  vs  $489 \pm 231$  mg/day;  $P < 0.001$ ) but also increased plasma levels of CBZ ( $9.84 \pm 4.37$  vs  $7.41 \pm 3.43$   $\mu\text{g/mL}$ ;  $P < 0.001$ ) compared to patients responsive to CBZ treatment. CBZ resistance was not related to any of the SNPs investigated.

## Conclusions

The SCN1A IVS5-91G>A SNP is associated with susceptibility to epilepsy. SNPs in EPHX1 gene are influencing CBZ metabolism and disposition. CBZ plasma levels are not an indicator of resistance to the therapy.

## Introduction

Epilepsy is a disease that cannot be described by only a single condition, but it rather represents a family of diverse disorders, having in common an abnormally increased predisposition to seizures, which occur due to abnormal, excessive or synchronous brain neuronal activity [1]. Prevalence of epilepsy is higher in developing countries and also slightly higher in lower socio-economic classes. It occurs in all strata in a population, and males are more predisposed compared to females. About 40% of patients develop epilepsy below the age of 16 years and about 20% over the age of 65 years, with a frequency that different studies have shown to vary between 50 and 120 per 100,000 individuals per year [2]. Carbamazepine (CBZ) belongs to one of the most prescribed anticonvulsant drugs for treatment of generalized tonic-clonic and complex partial epileptic seizures [3]. As several other antiepileptic drugs, CBZ is a substrate of the human P-glycoprotein (Pgp) transporter [4]. CBZ is metabolized in the liver through an oxidative, epoxidase pathway catalyzed by CYP3A4 and other CYP enzymes followed by epoxide hydrolase mediated pathway. This leads to the formation of CBZ-10,11-epoxide (CBZ-E), the major CBZ metabolite, which possesses a potent anticonvulsant effect, before further metabolism by microsomal epoxide hydrolase (mEH) and excretion as inactive CBZ-10,11-diol (CBZ-diol) [5,6].

From the pharmacological point of view, CBZ exerts a combined antiepileptic action by use-dependent blockage of neuronal sodium channels in a voltage and frequency dependent manner by delaying their recovery from the inactivated state, through reduction of the number of action potentials within a burst and decrease of burst duration [7,8].

Clinically, CBZ is characterized by important inter and/or intraindividual variation in drug pharmacokinetics and by different patient susceptibility to adverse reactions. As a consequence, the therapeutic efficacy of CBZ, as well as those of other similar antiepileptic drugs, seems to correlate better with blood levels than with doses [9,10]. For these reasons, therapeutic drug monitoring emerged as an essential tool for therapy optimization and for minimizing the side effects arising due to excessive drug blood concentrations (or to avoid lack of pharmacological effect due to its lower than expected blood levels) [11].

In addition, and above all, as seizures can effectively be pharmacologically suppressed, a high percentage of patients (30–40%) exhibit pharmacoresistance independently from

medication non-compliance, significant provoking factors, inappropriate drug or doses, or progressive neurological diseases [12,13]. The main proposed cause for CBZ pharmacoresistance is the genetic polymorphism existing in genes encoding for proteins associated with CBZ metabolizing enzymes (mediated by CYP3A4, CYP3A5, CYP2C9, CYP2C19 and EPHX1), transporter proteins (ABCB1, ABCC1), or target proteins and receptors (SCN1A, SCN2A). Understanding of these may enable prediction of drug resistance and optimization of therapeutic strategies [14–18]. However, studies investigating the effect of SNPs of a variety of genes on CBZ metabolism in different populations have achieved, in several cases, contradictory conclusions, probably due to geographical/genetically differences existing among the studied populations [19–28].

The present study aimed to evaluate the potential associations between SNPs of key genes encoding for the major drug transporter protein ABCB1, for the metabolizing enzyme EPHX1, and for the sodium channel SCN1A, as genes involved in the metabolism and disposition of CBZ, and CBZ plasma levels in epileptic patients treatment.

## Materials and Methods

### Subjects

All the procedures in this study were conducted according to guidelines in the Declaration of Helsinki and the study design was approved by Ethics Committee in Faculty of Medicine, University of Prishtina—Hasan Prishtina and University Clinical Center of Kosovo (Prishtina, Kosovo). All patients gave written informed consent. A total of 145 patients with epilepsy (82 males and 63 females) between the ages of 18–70 years were included in the study. Patients were treated with CBZ monotherapy for at least 1 year at Neurology Clinic in the University Clinical Center of Prishtina. All patients were not receiving pharmacological treatment for other pathologies. Patients' renal and hepatic functions were evaluated and those with abnormal function were not included in the study. The classification of epilepsies and epileptic syndromes were conducted according to the guidelines of the International League Against Epilepsy [29]. A total of 100 unrelated healthy control individuals were also randomly recruited from the same region and ethnicity to compare genotyping distribution. All patient were from Kosovo and the following information was noted: gender, weight (kg), age, CBZ maintenance dose (mg/kg per day), drug resistant patients (considered as occurrence of at least four seizures over a period of 1 year during treatment with CBZ) and drug responsive patients (those seizure-free for at least 1 year during treatment with CBZ) (Table 1). No dose adjustments were allowed within 1 month prior to the collection of samples to ensure steady-state plasma concentrations of CBZ.

A total of 6 mL of fasting peripheral blood was drawn early in the morning from each patient in EDTA and heparinized vacutainer blood collection tubes for DNA extraction and analysis of plasma concentrations of CBZ and of its major metabolites.

The maintenance dose-adjusted concentrations of CBZ, CBZE and CBZD ( $CDR_{CBZ}$ ,  $CDR_{CBZE}$ ,  $CDR_{CBZD}$ ) and the CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios were used as parameters for the evaluation of CBZ metabolism.

### Genotyping

Genomic DNA was extracted from whole blood using a Purelink Genomic DNA extraction kit according to the procedure recommended by the manufacturer (Invitrogen, CA, USA). The genotypes of *ABCB1* c.3435C>T (rs1045642), *SCN1A* c.3184A>G (rs2298771), IVS5–91 G>A (rs3812718), and *EPHX1* c.416A>G (rs2234922), c.337T>C (rs1051740), polymorphisms were analyzed using SNP specific Taqman probes Vic and Fam reporter dyes,

**Table 1. Patient characteristics and dose-adjusted concentrations and reciprocal ratios of CBZ and its major metabolites CBZE and CBZD.** CBZE: carbamazepine-10,11-epoxide; CBZD: 10,11-dihydroxy-carbamazepine.

Characteristics	Patients	Controls
Total patients (n)	145	100
Sex (male/female)	82/63	58/42
Age (years)	32.9±15.5	30.4±14.4
Weight (Kg)	68.3±16.0	66.5±15.5
CBZ maintenance dose (mg/Kg per day)	8.18±3.91	-
Drug resistance/response	48/97	-
CBZ plasma concentration (µg/mL)	6.78±2.78	-
CDR <sub>CBZ</sub> (µg/mL per mg/Kg)	0.56±0.55	-
CBZE plasma concentration	0.74±0.48	-
CDR <sub>CBZE</sub> (µg/mL per mg/Kg)	0.24±0.18	-
CBZD plasma concentration	1.81±1.38	-
CDR <sub>CBZD</sub> (µg/mL per mg/Kg)	0.24±0.18	-
CBZD:CBZE	2.99±2.57	-

doi:10.1371/journal.pone.0142408.t001

according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA). DNA samples were diluted to a concentration of 10 ng/µL. The assays were run using a reaction volume of 15 µL, consisting of 7.5 µL of Applied Biosystems TaqMan Genotyping Master Mix, 0.75 µL of TaqMan SNP Genotyping Assays and Drug Metabolism Genotyping Assays, 1.75 µL of DNase/RNase free water and 5 µL of diluted DNA. Initial denaturation step was 7 minutes and 30 seconds, followed by 45 cycles of 15 at 92°C and anneal/extend for 1 min at 60°C on a iCycler iQ™ Real-Time PCR Detection System BioRad Machine.

### Determination of CBZ, CBZE and CBZD by HPLC-UV-DAD

Plasma samples for analyses were obtained from whole blood by centrifugation at 4000 rpm for 4 minutes. Measurement of plasma CBZ, CBZE and CBZD was carried out using an Ultra Fast Liquid Chromatographic System (Schimadzu-Japan).

Chromatographic separations were done using a reversed-phase column (KINETEX C18 5 µm, 150 x 4.6 mm i.d., Phenomenex, Castel Maggiore, Bologna, Italy), run in isocratic conditions with acetonitrile/water (20:80) mobile phase at a flow rate of 1.5 ml/min. Column temperature was 25°C. The DAD detector operated between 200 nm and 400 nm, and the monitoring wavelengths were set at λ = 285 nm for CBZ monitoring, λ = 250nm for phenacetin and λ = 215 nm for CBZE and CBZD. Method validation was developed following recommendation for validation of bioanalytical methods of European Medicine Agency guideline.

Sample preparation was carried out using solid-phase extraction. Calibration curves were built using blank plasma spiked with previously prepared standards for analyses from stock solutions of CBZ, CBZE and CBZD (Sigma-Aldrich). OASIS Hydrophobic-Lipophilic-Balanced sorbent cartridges (HLB, 30mg, Waters Corporation, Millford, MA) were used for extraction. Cartridges were first preconditioned with 1 mL of pure methanol, followed by washing out of the solvent with 1 mL of MilliQ water. 50 µL of IS solution (25 µg/mL phenacetin in methanol) was added to each 250 µL sample, followed by sample vortex-mixing for 30 seconds, centrifugation at 6000 G and supernatant loading on solid phase extraction cartridge. After washing with 1 mL of 5% methanol in MilliQ water, analytes were recovered with 500 µL of absolute methanol and 10 µL injected in the HPLC system.

## Statistical analysis

All data were expressed as mean and standard deviation (SD). Before statistical analysis, normal distribution and homogeneity of the variances were tested. Associations between the experimental parameters were investigated using one-way ANOVA, followed by *t*-tests on pairwise comparisons with the least square difference (LSD) *post hoc* adjustment for multiple comparisons. Apparent CBZ clearance (CL) was calculated according to the formula:

$$CL = F \frac{CBZ_{\text{maintenance dose}}}{CBZ_{\text{plasma concentration}} \times (\tau)}$$

where  $CBZ_{\text{plasma concentration}}$  is plasma CBZ concentration at steady state, *F* is bioavailability and ( $\tau$ ) is the dosing interval [30,31]. Genotype frequencies were checked with Hardy—Weinberg equilibrium using  $\chi^2$  test. The relationship between various genotypes and responsiveness was examined using binary logistic regression. Associations were expressed as odds ratios (OR) or risk estimates with 95% confidence intervals (CI) and considered significant when *P*-value was <0.05. Statistical analysis was performed using the R-commander GUI for R (v. 3.1.3) [32].

## Results

### Quantitative determination of CBZ, metabolites and related parameters

CBZ daily dose showed direct correlations with the plasma levels of both CBZ ( $R = 0.58$ ,  $P < 0.001$ ) and CBZE ( $R = 0.37$ ,  $P < 0.001$ ) (S1 Fig). Plasma concentrations of the active metabolite, CBZ-10,11-epoxide (CBZE), were significantly correlated to CBZ plasma levels ( $R = 0.58$ ,  $P < 0.001$ ; Fig 1).

### Impact of sodium channel SNPs on the prevalence of epilepsy


We first studied whether two SNPs in sodium channel (SCN1A) affect the prevalence of epilepsy. Genotyping these two SNPs in epileptic patients and healthy controls revealed that carriers of the SCN1A IVS5-91G>A variant were at increased risk of epilepsy susceptibility ( $P = 0.033$ ; OR 1.80, 95% CI 1.048, 3.094), while no impact for SCN1A c.3184A>G SNP was observed (Fig 2). Data regarding the prevalence of all the SNPs investigated in epileptic patients compared to controls are shown in (S1 Table).

### Impact of gene variants in genes influencing CBZ metabolism and disposition parameters and CBZ metabolite plasma levels

Patients carrying the AA variant/genotype of the SCN1A IVS5-91G>A gene showed increased maintenance dosage (Fig 3B), reduced CBZ plasma levels (Fig 3C) and increased CBZD to CBZ ratio (Fig 3D) (Table 2), despite taking higher CBZ daily dosage compared to GA or GG carriers ( $694 \pm 313$  mg/day for AA compared to  $509 \pm 248$  mg/day for GA and  $531 \pm 254$  mg/day for GG.  $P < 0.05$ , Fig 3A).


Whether these differences could be the consequence of a different pharmacodynamic response to CBZ in carriers with AA compared to GA or GG carriers, remains to be addressed. Furthermore, no significant difference in CBZ CL values associated with any of the SNPs investigated in this study, or with patients CBZ responsiveness/resistance, was observed (results not shown).

SCN1A c.3184A>G SNP does not affect CBZ metabolism (Table 2). The same observation applies to ABCB1 3435C>T, where differences in daily dosage of CBZ are lost following adjustment for body weight (Table 2). Similarly, plasma levels of CBZ and its metabolites were not




**Fig 1. Correlation between CBZ and CBZE plasma concentrations (Pearson’s correlation coefficient R).**

doi:10.1371/journal.pone.0142408.g001



**Fig 2. Graphical representation of adjusted odds ratio and 95% confidence intervals according to the SCN1A genes polymorphism; genotype and allele frequencies in epilepsy patients vs. healthy control subjects.**

doi:10.1371/journal.pone.0142408.g002



**Fig 3. Graphical representations (box-plot) of the sodium channels (SCN1A IVS5-91 G>A) SNPs genotypes associations with (A) CBZ daily dosage (mg/day), (B) CBZ maintenance dose (mg/kg per day), (C) CDR<sub>CBZ</sub> and (D) CBZD:CBZ.** Statistical significance for difference of means is shown (P values, one way ANOVA analysis followed by Student's T-test).

doi:10.1371/journal.pone.0142408.g003

affected by these two SNPs (Table 2). GG carriers of the EPHX1 c.416A>G SNP showed a reduced CBZ metabolism (mediated by CYP oxidation followed by microsomal epoxide hydrolyase activity) compared to AA carriers as reflected by a significantly decreased ratio of CBZD to CBZ ( $0.13 \pm 0.08$  to  $0.26 \pm 0.17$ ;  $P < 0.05$ , Fig 4A), CBZD to CBZE ratio ( $1.74 \pm 1.06$  to  $3.08 \pm 2.90$ ,  $P < 0.05$ ) (Fig 4B) and CDR<sub>CBZD</sub> ( $0.13 \pm 0.08$  to  $0.24 \pm 0.19$   $\mu\text{g/mL per mg/Kg}$ ;  $p < 0.05$ , Fig 4C) (Table 2). It is worth noting that another SNP in EPHX1 (c.337T>C) affected CBZ plasma levels in carriers of the rare allele, showing significant lower CDR<sub>CBZ</sub> compared to carriers of the wild type allele (TT  $0.94 \pm 0.49$   $\mu\text{g/mL per mg/Kg}$ , CC  $0.76 \pm 0.16$   $\mu\text{g/mL per mg/Kg}$ ;  $P < 0.05$ , Fig 5) (Table 2). In summary, SNPs in EPHX1 might affect microsomal epoxide hydrolyase activity and plasma CBZ levels.

**Table 2. CBZ daily dose, maintenance dose, concentration/dose adjusted ratios of CBZ, CBZE, CBZD and their concentration ratios stratified by individual SNPs genotypes.** Data are mean ± standard deviations.


SNP	n	CBZ daily dose (mg/day)	CBZ maintenance dose (mg/Kg per day)	CDR <sub>CBZ</sub> (µg/mL per mg/Kg)	CDR <sub>CBZE</sub> (µg/mL per mg/Kg)	CDR <sub>CBZD</sub> (µg/mL per mg/Kg)	CBZE: CBZ	CBZD: CBZ	CBZD: CBZE
<b>SCN1A IVS5-91G&gt;A</b>									
<b>rs3812718</b>									
GG	50	509.3±248.0 <sup>a</sup>	7.79±3.90 <sup>a</sup>	1.11±0.69 <sup>a</sup>	0.12±0.13 <sup>a</sup>	0.23±0.15 <sup>a</sup>	0.10 ±0.06 <sup>a</sup>	0.23 ±0.13 <sup>a</sup>	3.00 ±2.45 <sup>a</sup>
GA	79	531.6±249.2 <sup>a</sup>	7.96±3.46 <sup>a</sup>	0.92±0.46 <sup>a</sup>	0.10±0.07 <sup>a</sup>	0.23±0.19 <sup>a</sup>	0.13 ±0.12 <sup>a</sup>	0.27 ±0.22 <sup>a</sup>	2.78 ±2.44 <sup>a</sup>
AA	16	693.8 ±313.0 <sup>b*</sup>	10.48±5.32 <sup>b*</sup>	0.71±0.28 <sup>b*</sup>	0.08±0.04 <sup>a</sup>	0.28±0.10 <sup>a</sup>	0.14 ±0.08 <sup>a</sup>	0.43 ±0.17 <sup>b**</sup>	4.20 ±3.17 <sup>a</sup>
<b>SCN1A c.3184A&gt;G</b>									
<b>rs2298771</b>									
AA	25	524.0±238.5 <sup>a</sup>	7.57±3.85 <sup>a</sup>	1.13±0.71 <sup>a</sup>	0.11±0.11 <sup>a</sup>	0.22±0.14 <sup>a</sup>	0.11 ±0.06 <sup>a</sup>	0.22 ±0.14 <sup>a</sup>	2.87 ±2.56 <sup>a</sup>
AG	83	522.9±245.5 <sup>a</sup>	8.06±3.66 <sup>a</sup>	0.93±0.49 <sup>a</sup>	0.10±0.08 <sup>a</sup>	0.24±0.20 <sup>a</sup>	0.12 ±0.12 <sup>a</sup>	0.26 ±0.21 <sup>a</sup>	2.98 ±2.59 <sup>a</sup>
GG	37	596.4±313.8 <sup>a</sup>	8.86±4.16 <sup>a</sup>	0.93±0.58 <sup>a</sup>	0.11±0.13 <sup>a</sup>	0.23±0.11 <sup>a</sup>	0.12 ±0.06 <sup>a</sup>	0.29 ±0.16 <sup>a</sup>	3.02 ±2.62 <sup>a</sup>
<b>ABCB1 3435C&gt;T</b>									
<b>rs1045642</b>									
CC	26	440.4±210.7 <sup>a</sup>	7.78±4.51 <sup>a</sup>	0.98±0.36 <sup>a</sup>	0.12±0.10 <sup>a</sup>	0.26±0.23 <sup>a</sup>	0.11 ±0.06 <sup>a</sup>	0.23 ±0.14 <sup>a</sup>	2.55 ±1.64 <sup>a</sup>
CT	85	594.4 ±270.0 <sup>b*</sup>	8.56±3.88 <sup>a</sup>	0.92±0.49 <sup>a</sup>	0.10±0.06 <sup>a</sup>	0.22±0.14 <sup>a</sup>	0.12 ±0.10 <sup>a</sup>	0.26 ±0.17 <sup>a</sup>	2.98 ±2.57 <sup>a</sup>
TT	34	525.4±253.3 <sup>a</sup>	8.05±3.59 <sup>a</sup>	1.00±0.66 <sup>a</sup>	0.11±0.13 <sup>a</sup>	0.21±0.15 <sup>a</sup>	0.11 ±0.06 <sup>a</sup>	0.24 ±0.16 <sup>a</sup>	3.36 ±3.18 <sup>a</sup>
<b>EPHX1 c.416A&gt;G</b>									
<b>rs2234922</b>									
AA	80	542.8±251.4 <sup>a</sup>	8.11±3.49 <sup>a</sup>	1.00±0.62 <sup>a</sup>	0.12±0.12 <sup>a</sup>	0.24±0.19 <sup>a*</sup>	0.12 ±0.09 <sup>a</sup>	0.26 ±0.17 <sup>a*</sup>	3.08 ±2.90 <sup>a</sup>
AG	55	540.0±276.0 <sup>a</sup>	8.16±4.27 <sup>a</sup>	0.94±0.53 <sup>a</sup>	0.09±0.05 <sup>a</sup>	0.21±0.14 <sup>b</sup>	0.11 ±0.08 <sup>a</sup>	0.24 ±0.17 <sup>b</sup>	3.95 ±2.44 <sup>a</sup>
GG	10	510.0±202.5 <sup>a</sup>	8.37±2.69 <sup>a</sup>	1.05±0.29 <sup>a</sup>	0.09±0.05 <sup>a</sup>	0.13±0.08 <sup>b</sup>	0.10 ±0.06 <sup>a</sup>	0.13 ±0.08 <sup>b</sup>	1.74 ±1.06 <sup>b*</sup>
<b>EPHX1 c.337T&gt;C</b>									
<b>rs1051740</b>									
TT	63	523.2±257.3 <sup>a</sup>	8.25±4.07 <sup>a</sup>	0.94±0.49 <sup>a</sup>	0.12±0.12 <sup>a</sup>	0.26±0.16 <sup>a</sup>	0.13 ±0.12 <sup>a</sup>	0.31 ±0.22 <sup>a*</sup>	3.29 ±2.69 <sup>a</sup>
TC	72	553.6±279.4 <sup>a</sup>	8.07±3.96 <sup>a</sup>	1.02±0.64 <sup>a</sup>	0.10±0.07 <sup>a</sup>	0.22±0.18 <sup>a</sup>	0.11 ±0.09 <sup>a</sup>	0.23 ±0.16 <sup>b</sup>	2.86 ±2.74 <sup>a</sup>
CC	10	620.0±147.6 <sup>a</sup>	9.26±2.85 <sup>a</sup>	0.76±0.15 <sup>b*</sup>	0.07±0.05 <sup>a</sup>	0.18±0.17 <sup>a</sup>	0.10 ±0.07 <sup>a</sup>	0.25 ±0.17 <sup>b</sup>	3.20 ±3.06 <sup>a</sup>

<sup>a,b</sup> Values sharing same letter are not significantly different.

\*P<0.05

\*\*P<0.01. (one way ANOVA analysis followed by Student's T-test). CBZE: carbamazepine-10,11-epoxide; CBZD: 10,11-dihydroxy-carbazepine.

doi:10.1371/journal.pone.0142408.t002




**Fig 4. Graphical representations (box-plot) of the EPHX1 c.416A>G genotypes associations with (A) CBZD:CBZ, (B) CBZD:CBZE and (C) CDR<sub>CBZD</sub>.** CBZ: Carbamazepine; CBZD: Carbamazepine-10,11-trans dihydrodiol; CBZE: Carbamazepine-10,11-epoxide; CDR: Concentration/dose ratio. Data are mean ± standard deviations. Statistical significance for difference of means is shown (P values, one way ANOVA analysis followed by Student's T-test).

doi:10.1371/journal.pone.0142408.g004

In addition, according to the report by Puranik et al. for a Caucasian population [17], haplo-type analysis of EPHX1 gene was carried out and no significant association was found with the above parameters (S2 Fig).


### Assessment of CBZ resistance

Finally, we assessed whether the plasma levels of CBZ and its metabolites represent markers of responsiveness to CBZ treatment. While increased CBZ daily and maintenance doses in



**Fig 5. Graphical representations (box-plot) of the EPHX1 c.377T>C genotypes with CDR<sub>CBZ</sub> CBZ: Carbamazepine; CDR: Concentration/dose ratio.** Data are mean ± standard deviations. Statistical significance for difference of means is shown (P values, one way ANOVA analysis followed by Student's T-test).

doi:10.1371/journal.pone.0142408.g005



**Fig 6. Graphical representations (box-plot) of the assessment of CBZ resistance due to patient response to therapy (A) CBZ daily dosage (mg/day), (B) CBZ maintenance dose (mg/kg per day) and (C) CBZ plasma concentration (µg/mL).** Data are mean ± standard deviations. Statistical significance for difference of means is shown (P values, Student's T-test).

doi:10.1371/journal.pone.0142408.g006

resistant patients compared to responsive patients ( $657 \pm 285$  vs  $489 \pm 231$  mg/day;  $P < 0.001$ ) (Fig 6A and 6B) are expected, the observation that resistant patients also presented increased CBZ plasma levels ( $9.84 \pm 4.37$  vs  $7.41 \pm 3.43$  µg/mL;  $P < 0.001$ ) (Fig 6C) is surprising.

To verify whether the differences in CBZ plasma levels were only due to the increased daily CBZ dose or maintenance dose, resistant and responsive patients were matched according to the dose of CBZ administered, by excluding  $n = 43$  patients taking the lowest CBZ doses from the responsive group. The results of this analysis showed that CBZ plasma levels were still increased in resistant patients compared to responsive patients (S2 Table).

Indeed, none of the SNPs investigated here resulted in association with CBZ drug responsiveness in epilepsy patients (Table 3).

## Discussion

The present study investigated the effects of polymorphism of genes encoding the major drug transport, metabolizing enzymes and target proteins, on plasma concentrations of CBZ and its related metabolites (CBZE and CBZD). This was conducted in order to detect the interindividual variability in Kosovar patients of Albanian ethnicity with respect to CBZ pharmacodynamics, as well as its metabolism and disposition in patients with epilepsy.

Our results show that the mean concentrations of CBZ, CBZE and CBZD and their ratios in our cohort were comparable to those previously reported for other Oriental and Caucasian populations [17–19,21,28]. In addition, the correlation coefficients observed between daily dose and plasma CBZ and CBZE were in agreement with those reported by Krasniqi et al. for a German population of epileptic patients [33].

Our study has three key findings: (i) the SCN1A IVS5-91G>A SNP is associated with susceptibility to epilepsy, (ii) SNPs in EPHX1 gene influence CBZ pharmacokinetic and (iii) CBZ plasma level is not an indicator of resistance to the therapy.

The sodium channel  $\alpha$ -subunit is the major binding site of several antiepileptic drugs. Therefore, the interest in genes encoding for this protein lies not only in the possible causal roles in epilepsy, but also in the potential effects on the antiepileptic drug efficacy.

There are several isoforms of  $\alpha$ -subunits expressed in the brain, which are encoded by SCN1A, 2A, 3A and 8A [34,35]. Differential influence of genetic variants, namely SCN1A c.3184A>G and SCN1A IVS5-91, in epilepsy susceptibility and drug response have previously

**Table 3. Distribution of SCN1A, ABCB1, EPHX1 genes polymorphism in drug-resistant and drug-responsive epileptic patients.**

SNPs	Gene/alleles	CBZ Resistance(n = 46)	CBZ Responsive (n = 99)	Odds Ratio (95% CI)	P-Value
<b>SCN1A IVS5-91G&gt;A</b> <b>rs3812718</b>	GG	16 (34.8%)	34 (34.3%)	reference	
	GA	25 (54.3%)	54 (54.6%)	0.98 (0.460, 2.104)	0.97
	AA	5 (10.9%)	11 (11.1%)	0.97 (0.287, 3.248)	0.96
	GG	16 (34.8%)	34 (34.3%)	reference	
<b>SCN1A c.3184A&gt;G</b> <b>rs2298771</b>	GA+AA	30 (65.2%)	65 (65.7%)	0.98 (0.470, 2.045)	0.97
	AA	8 (17.4%)	17 (17.2%)	reference	
	AG	27 (58.7%)	56 (56.5%)	1.02 (0.393, 2.669)	0.96
	GG	11 (23.9%)	26 (26.3%)	0.90(0.300, 2.693)	0.85
<b>ABCB1 3435C&gt;T</b> <b>rs1045642</b>	AA	8 (17.4%)	17 (17.2%)	reference	
	AG+GG	38 (82.6%)	82 (82.8%)	0.99 (0.391, 2.481)	0.97
	CC	8 (17.4%)	18 (18.2%)	reference	
	CT	28 (60.9%)	57 (57.6%)	1.11 (0.428, 2.851)	0.84
<b>EPHX1 c.416A&gt;G</b> <b>rs2234922</b>	TT	10 (21.7%)	24 (24.2%)	1.06(0.421, 2.643)	0.91
	CC	8 (17.4%)	18 (18.2%)	reference	
	CT+TT	38 (82.6%)	81 (81.8%)	1.06(0.421, 2.643)	0.91
	AA	25 (54.4%)	55 (55.6%)	reference	
<b>EPHX1 c.337T&gt;C</b> <b>rs1051740</b>	AG	18 (39.1%)	37 (37.3%)	1.07(0.513, 2.233)	0.86
	GG	3 (6.5%)	7 (7.1%)	0.94(0.225, 3.950)	0.94
	AA	25 (54.4%)	55 (55.6%)	reference	
	AG+GG	21 (45.6%)	42 (43.8%)	1.05 (0.543,2.228)	0.79
<b>EPHX1 c.337T&gt;C</b> <b>rs1051740</b>	TT	23 (50%)	40 (40.4%)	reference	
	TC	21 (45.6%)	51 (51.5%)	0.72 (0.348,1.474)	0.36
	CC	2 (4.4%)	8 (8.1%)	0.44(0.085,2.224)	0.31
	TT	23 (50%)	40 (40.4%)	reference	
	TC+CC	23(50%).	59 (59.6%)	0.68 (0.335, 1.370)	0.28

doi:10.1371/journal.pone.0142408.t003

been reported [36–38]. These two SNPs were selected since, by belonging to a linkage disequilibrium block, they can be representative of other SNPs in the SCN1A gene [15,39].

Our results, which show increased mean CBZ maintenance dose, lower CDR<sub>CBZ</sub> and higher CBZD:CBZ ratio in carriers of the IVS5-91G>AG variant of the SCN1A channel, are in agreement with previous findings in Caucasian patients [40,41]. Similar results were reported by Hung and colleagues, which showed in a Taiwanese population that carriers of the variant SCN1A IVS5–91G>A required higher CBZ dosages and lower ln(concentration–dose ratios) compared to noncarriers [15]. Recently, these patterns have been confirmed by Ma and colleagues in a population of Chinese patients [42]. Furthermore, increased doses of CBZ are associated with increased mean steady-state concentrations of CBZD [43], which could be linked to the effect of the SCN1A gene, IVS5–91 G>A variant, on CBZ dosage and CBZD:CBZ ratio.

Not all papers are in agreement with the findings above [44,45]. Whether ethnicity plays a role, remains to be addressed.

In addition, we also observed genetic variations in the genes encoding the expression of cerebral sodium channels in the epilepsy phenotypes compared to healthy control subjects, suggesting the involvement of this genotype in increased risk for developing epilepsy. These findings warrant further confirmation in future studies involving larger cohorts.

Previously, the impact of variants on a drug efflux transporter protein involved in the efflux of antiepileptic drugs, namely P-glycoprotein (Pgp; encoded by ABCB1 or MDR1), has been studied in different ethnic groups [46,47]. However, conflicting results have been reported,

with some works indicating an impact on antiepileptic drug resistance [48–51], while others are in agreement with our observation, showing no effect of ABCB1 3435C>T on CBZ pharmacokinetic and drug response [52–55].

CYP3A4/A5 enzymes play a major role in the CBZ metabolism and in the onset of epilepsy pharmacoresistance [56–58]. Subsequent analyses aimed at addressing the contribution of CYP3A4 protein variants to the inter-individual variability of CYP3A4 activity were, however, less clear [59] or even observed a lack of effect of CYP3A4/5 variants on CBZ metabolism in both European Caucasian or in Asian populations [17,21,60,61].

For this reason, we decided to focus the investigation on the impact of SNPs in other genes that could explain CBZ pharmacoresistance beyond those in CYP3A4/A5 enzymes, including mEH, which has been proposed as a predictor of maintenance dose [27].

The human mEH, encoded by the EPHX1 gene, is expressed polymorphically [62]. The presence of two common variants, c.337T>C and c.416A>G, has been suggested to influence the catalytic activity of mEH in vitro and in vivo [63,64]. Further studies have shown that enzymatic expression levels and activity are altered and a significant association of EPHX1 SNPs with increased or decreased CBZD:CBZE ratios was found [15, 65–68], although this was not consistent in all studies [21]. While CBZD:CBZ is an indicator of enzymatic conversion of CBZ, dependent on both CYP enzymes and/or mEH, useful in determining unexpected CBZ levels [69], CBZD:CBZE ratio is considered as a sensitive indicator of mEH activity [15, 65–68]. This ratio was significantly lower in carriers of the variant EPHX1 c.416A>G, suggesting a reduced activity of the mEH, while the similarity of CBZE:CBZ ratio in carriers versus non carriers limits the relevance of differences in CYP enzyme activity.

We show here that variants in EPHX1 affect CBZ metabolism, either resulting in no effect on  $CDR_{CBZ}$  or reduced CBZD:CBZ, CBZD:CBZE ratios and  $CDR_{CBZD}$ , which is in agreement with reports by Nakajima et al. [67] in the case of c.416A>G. We also observed that another EPHX1 variant (c.337T>C) is associated with lower  $CDR_{CBZ}$ , in agreement with associations found by other authors [15,27]. However, as it is known that CBZ is not a direct substrate of mEH, the possibility of using CBZ plasma levels as a surrogate indicator for the evaluation of mEH activity has to be considered.

Previous studies have shown that SCN1A splice variants (encoding  $Na_v$  I.I channels) play a role in epilepsy susceptibility, with recent evidence of drug sensitivity due to tonic and use-dependent block of  $Na_v$ 1.1-5A and  $Na_v$ 1.1-5N, with therapeutically CBZ concentrations, showing more preferential activity for other reported AEDs than CBZ. [70,71]

Finally, we observed that resistant patients presented significantly increased daily dose, maintenance dose and plasma levels of CBZ. To exclude that the latter could simply be the consequence of increased administered dose, we compared responsive and resistant patients matched for the daily dose and still observed significantly increased plasma CBZ levels. Previous studies showed that in resistant patients access of CBZ to the brain was limited by the blood-brain barrier [72–74]. Whether this could, at least in part, explain our findings remains to be explored.

In conclusion, by showing a critical effect of polymorphisms in the response and efficacy of CBZ treatment in epileptic patients with a main focus on CBZ and metabolites, our work may set the stage for larger investigational studies aimed at evaluating the impact of pharmacogenomic approaches in the clinical management of patients with epilepsy.

## Supporting Information

**S1 Dataset. Original Study Dataset.**  
(XLSX)

**S1 Fig. Correlation between CBZ daily dose and (a) plasma concentration of CBZ and (b) plasma correlation of CBZE.** CBZE: carbamazepine-10,11-epoxide.  
(TIF)

**S2 Fig. Graphical representation (boxplot) of the relationship between CBZD:CBZE ratio and EPHX1 SNPs (rs1051740-Tyr113His and rs2234922-His139Arg) diplotypes.**  $P > 0.05$  (one way ANOVA). CBZ E: carbamazepine-10,11-epoxide; CBZD: 10,11-dihydroxy-carbamazepine.  
(TIF)

**S1 Table. Distribution of SCN1A, ABCB1, EPHX1 genes polymorphisms; genotype and allele frequencies in epileptic patients vs. healthy subjects.**  
(DOCX)

**S2 Table. CBZ daily dose, CBZ maintenance dose and CBZ plasma level stratified by response to CBZ therapy (responsive vs resistance patients) and corresponding P values for their difference of means (Student's t-test).** To match the average CBZ daily doses,  $n = 43$  subjects with the lowest CBZ daily dosages were excluded from the analysis ( $P > 0.05$ ). Data are mean  $\pm$  standard deviation.  
(DOCX)

## Author Contributions

Conceived and designed the experiments: AD GDN GB SHK. Performed the experiments: AD SHK GB AS VG. Analyzed the data: AD GDN GB SHK DV. Contributed reagents/materials/analysis tools: AD GB GDN SHK. Wrote the paper: AD SHK GDN GB DV.

## References

1. Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. 1994; 46(4):470–472.
2. Shorvon SD. Handbook of epilepsy treatment. In: Definitions and Epidemiology. London: John Wiley & Sons; 2010. p. 1–6.
3. Kwan P, Martin JB. Effectiveness of first antiepileptic drug. *Epilepsia*. 2010; 42(10):1255–1260.
4. Luna T, Carlos MF, Wolfgang L. Several major antiepileptic drugs are substrates for human P-glycoprotein. *Neuropharmacology*. 2008; 55(8):1364–1375. doi: [10.1016/j.neuropharm.2008.08.032](https://doi.org/10.1016/j.neuropharm.2008.08.032) PMID: [18824002](https://pubmed.ncbi.nlm.nih.gov/18824002/)
5. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzales FJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. *Biochem pharmacol*. 1994; 47(11):1969–1979. PMID: [8010982](https://pubmed.ncbi.nlm.nih.gov/8010982/)
6. Bertilson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. An update. *Clin Pharmacokinet*. 1986; 11(3):177–98. PMID: [3524954](https://pubmed.ncbi.nlm.nih.gov/3524954/)
7. Szoek CE, Newton M, Wood JM, Goldstein D, Berkovic SF, O'Brien TJ, et al. Update on pharmacogenetics in epilepsy: a brief review. *Lancet Neurol*. 2006; 5(2):189–196. PMID: [16426995](https://pubmed.ncbi.nlm.nih.gov/16426995/)
8. Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. *Genome Biol*. 2003; 4(3):207. PMID: [12620097](https://pubmed.ncbi.nlm.nih.gov/12620097/)
9. Patsalos PN. Antiepileptic drug pharmacogenetics. *Ther Drug Monit*. 2000; 22(1):127–130. PMID: [10688275](https://pubmed.ncbi.nlm.nih.gov/10688275/)
10. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Perucca E, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008; 49(7):1239–1276. doi: [10.1111/j.1528-1167.2008.01561.x](https://doi.org/10.1111/j.1528-1167.2008.01561.x) PMID: [18397299](https://pubmed.ncbi.nlm.nih.gov/18397299/)
11. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. *Ther Drug Monit*. 2005; 27(1):10–17. PMID: [15665740](https://pubmed.ncbi.nlm.nih.gov/15665740/)

12. Alexopoulos AV. Pharmacoresistant epilepsy: Definition and explanation. *Epileptology*. 2013; 1(1):38–42.
13. Arroyo AS, Brodie MJ, Avanzini G, Baumgartner C, Chiron C, Dulac O, et al. Is refractory epilepsy preventable?. *Epilepsia*. 2002; 43(4):437–444. PMID: [11952776](#)
14. Sisodiya SM. Genetics of drug resistance. *Epilepsia*. 2005; 46(10):33–38.
15. Hung CC, Chang WL, Ho JL, Tai JJ, Hsieh TJ, Huang HC, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. *Pharmacogenomics*. 2012; 13(2):159–169. doi: [10.2217/pgs.11.141](#) PMID: [22188362](#)
16. Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z, Zhong MK, et al. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. *Pharmacogenomics*. 2014; 15(10):1323–1336. doi: [10.2217/pgs.14.89](#) PMID: [25155934](#)
17. Puranik YG, Birnbaum AK, Marino SE et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. *Pharmacogenomics*. 2013; 14(1):35–45. doi: [10.2217/pgs.12.180](#) PMID: [23252947](#)
18. Taur SR, Kulkarni NB, Gandhe PP et al. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs. *J Postgrad Med*. 2014; 60(3):265. doi: [10.4103/0022-3859.138739](#) PMID: [25121365](#)
19. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. *Pharmacogenomics*. 2014; 15(15):1867–1879. doi: [10.2217/pgs.14.142](#) PMID: [25495409](#)
20. Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia*. 2011; 52(5):40–44.
21. Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, et al. Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients. *Pharmacogenomics Pers Med*. 2014; 7:117.
22. Hashi S, Yano I, Shibata M, Masuda S, Kinoshita M, Matsumoto R, et al. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. *Eur J Clin Pharmacol*. 2015; 71(1):51–58. doi: [10.1007/s00228-014-1773-z](#) PMID: [25323806](#)
23. Shaheen U, Prasad DKV, Sharma V. Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. *Epilepsy Res*. 2014; 108(2):251–256. doi: [10.1016/j.epilepsyres.2013.11.009](#) PMID: [24300029](#)
24. Menzler K, Hermsen A, Balkenhol K, Duddek C, Bugiel H, Bauer S, et al. A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability—A pharmacogenetic transcranial magnetic stimulation study. *Epilepsia*; 55(2):362–369. doi: [10.1111/epi.12515](#) PMID: [24417206](#)
25. Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children. *Mol Biol Rep*. 2014; 41(1):331–336. doi: [10.1007/s11033-013-2866-y](#) PMID: [24213830](#)
26. Sterjev Z, Trencvaska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, et al. The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. *Neuropsychiatr Dis Treat*. 2012; 8:191. doi: [10.2147/NDT.S28285](#) PMID: [22570551](#)
27. Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie M, et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. *Clinical Neuropharmacol*. 2009; 32(4):205–212.
28. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube N, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. *Pharmacogenomics*. 2006; 7(4):551–561. PMID: [16753003](#)
29. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010; 51(4):676–685. doi: [10.1111/j.1528-1167.2010.02522.x](#) PMID: [20196795](#)
30. Panomvana D, Traiyawong T, Towanabut S. Effect of CYP3A5 Genotypes on the Pharmacokinetics of Carbamazepine when used as Monotherapy or Co-Administered with Phenytoin, Phenobarbital or Valproic Acid in Thai Patients. *J Pharm Pharm Sci*. 2013; 16(4):502–510. PMID: [24210059](#)
31. Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, et al. Steady-State Carbamazepine Pharmacokinetics Following Oral and Stable-Labeled Intravenous Administration in Epilepsy

- Patients: Effects of Race and Sex. *Clin Pharmacol Ther.* 2012; 91(3):483–488. doi: [10.1038/clpt.2011.251](https://doi.org/10.1038/clpt.2011.251) PMID: [22278332](https://pubmed.ncbi.nlm.nih.gov/22278332/)
32. Fox J. Getting started with the R commander: a basic-statistics graphical user interface to R. *JStat Softw.* 2005; 14(9):1–42.
  33. Krasniqi S, Neziri B, Islami H, Bauer S. Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy. *Medical Arch.* 2010; 64(2):80–83.
  34. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. *Epilepsy Behav.* 2005; 7:18–36. PMID: [15979945](https://pubmed.ncbi.nlm.nih.gov/15979945/)
  35. Abou-Khalil B, Ge Q, Desai R, Ryther R, Bazyk A, Bailey R, et al. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. *Neurology.* 2001; 57:2265–2272. PMID: [11756608](https://pubmed.ncbi.nlm.nih.gov/11756608/)
  36. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. *Br J Clin Pharmacol.* 2009; 68(2):214–220. doi: [10.1111/j.1365-2125.2009.03437.x](https://doi.org/10.1111/j.1365-2125.2009.03437.x) PMID: [19694741](https://pubmed.ncbi.nlm.nih.gov/19694741/)
  37. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. *Br J Clin Pharmacol.* 2008; 66:304–307. doi: [10.1111/j.1365-2125.2008.03203.x](https://doi.org/10.1111/j.1365-2125.2008.03203.x) PMID: [18489610](https://pubmed.ncbi.nlm.nih.gov/18489610/)
  38. Kumari R, Lakhan R, Kumar S, Garg RK, Misra UK, Kalita J, et al. SCN1AIVS5-91G> A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. *Biochimie.* 2013; 95(6):1350–1353. doi: [10.1016/j.biochi.2013.02.006](https://doi.org/10.1016/j.biochi.2013.02.006) PMID: [23466530](https://pubmed.ncbi.nlm.nih.gov/23466530/)
  39. Fendri-Kriaa N, Boujilbene S, Kammoun F, Mkaouar-Rebai E, Ben Mahmoud A, Hsairi I, et al. A putative disease-associated haplotype within the SCN1A gene in Dravet syndrome. *Biochem Biophys Res Commun.* 2011; 408(4):654–657. doi: [10.1016/j.bbrc.2011.04.079](https://doi.org/10.1016/j.bbrc.2011.04.079) PMID: [21531204](https://pubmed.ncbi.nlm.nih.gov/21531204/)
  40. Sterjev Z, Kiteva G, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska T, et al. Influence of the SCN1A IVS5N+ 5 G>A polymorphism on therapy with carbamazepine for epilepsy. *Balkan J Med Genet.* 2012; 15(1):19. doi: [10.2478/v10034-012-0003-1](https://doi.org/10.2478/v10034-012-0003-1) PMID: [24052718](https://pubmed.ncbi.nlm.nih.gov/24052718/)
  41. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. *Proc Natl Acad Sci.* 2005; 102:5507–5512. PMID: [15805193](https://pubmed.ncbi.nlm.nih.gov/15805193/)
  42. Ma CL, Jiao Z, Wu XY, Hong Z, Wu ZY, Zhong MK. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. *Pharmacogenomics.* 2015; 16(13):1499–1512. doi: [10.2217/pgs.15.94](https://doi.org/10.2217/pgs.15.94) PMID: [26314341](https://pubmed.ncbi.nlm.nih.gov/26314341/)
  43. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. *Br J Clin Pharmacol.* 1992; 33(6):611. PMID: [1389933](https://pubmed.ncbi.nlm.nih.gov/1389933/)
  44. Zimprich F, Stogmann E, Bonelli S, Baumgartner C, Mueller JC, Meitinger T, et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. *Epilepsia.* 2008; 49(6):1108–1109. doi: [10.1111/j.1528-1167.2008.01549\\_4.x](https://doi.org/10.1111/j.1528-1167.2008.01549_4.x) PMID: [18554361](https://pubmed.ncbi.nlm.nih.gov/18554361/)
  45. Haerian BS, Baum L, Kwan P, Tan HJ, Raymond AA, Mohamed Z. SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. *Pharmacogenomics.* 2013; 14(10):1153–1166. doi: [10.2217/pgs.13.104](https://doi.org/10.2217/pgs.13.104) PMID: [23859570](https://pubmed.ncbi.nlm.nih.gov/23859570/)
  46. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. *Adv. Drug Deliv. Rev.* 2012; 64(10):930–942. doi: [10.1016/j.addr.2011.12.003](https://doi.org/10.1016/j.addr.2011.12.003) PMID: [22197850](https://pubmed.ncbi.nlm.nih.gov/22197850/)
  47. Hoffmeyer S, Burk O, Richter VO, Arnold PH, Brockmöller J, John A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci.* 2000; 97(7):3473–3478. PMID: [10716719](https://pubmed.ncbi.nlm.nih.gov/10716719/)
  48. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. *N Engl J Med.* 2003; 348(15):1442–1448. PMID: [12686700](https://pubmed.ncbi.nlm.nih.gov/12686700/)
  49. Ozgon GO, Bebek N, Gul G, Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. *Eur Neurol.* 2007; 59(1–2):67–70. PMID: [17917461](https://pubmed.ncbi.nlm.nih.gov/17917461/)
  50. Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y, et al. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. *Epilepsy Behav.* 2011; 21(1): 27–30. doi: [10.1016/j.yebeh.2011.02.015](https://doi.org/10.1016/j.yebeh.2011.02.015) PMID: [21493161](https://pubmed.ncbi.nlm.nih.gov/21493161/)
  51. Subenthiran S, Abdullah NR, Joseph JP, Muniandy PK, Mok BT, Kee CC, et al. Linkage disequilibrium between polymorphisms of ABCB1 and ABCB2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. *PloS one.* 2013; 8(5):e64827. doi: [10.1371/journal.pone.0064827](https://doi.org/10.1371/journal.pone.0064827) PMID: [23717663](https://pubmed.ncbi.nlm.nih.gov/23717663/)

52. Tan NCK, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. *Neurology*. 2004; 63(6):1090–1092. PMID: [15452306](#)
53. Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, Cho JY, et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. *Epilepsy Res*. 2009; 84(1):86–90. doi: [10.1016/j.eplepsyres.2008.12.001](#) PMID: [19167193](#)
54. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS, Zulkifli SZ, et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. *Seizure*. 2010; 19(6):339–346. doi: [10.1016/j.seizure.2010.05.004](#) PMID: [20605481](#)
55. Joseph V, Radhakrishnan K, Banerjee M. Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance. *PloS one*. 2014; 9(2):e89253. doi: [10.1371/journal.pone.0089253](#) PMID: [24586633](#)
56. Du J, Qinghe X, Xu L, Xu M, Shu A, Shi Y, et al. Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. *Pharmacogenomics*. 2006; 7(6):831–841. PMID: [16981844](#)
57. Park PW, Seo YH, Ahn JY, Kim KA, Park J. Effect of CYP3A5\* 3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. *J Clin Pharm Ther*. 2009; 34(5):569–574. doi: [10.1111/j.1365-2710.2009.01057.x](#) PMID: [19744012](#)
58. Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, et al. Effect of CYP3A5\* 3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. *Clin Pharmacol Ther*. 2006; 79(5):509–510. PMID: [16678552](#)
59. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, et al. Identification and functional characterization of eight CYP3A4 protein variants. *Pharmacogenet Genomics*. 2001; 11(5):447–458
60. Milovanovic DD, Radosavljevic I, Radovanovic M, Milovanovic JR, Obradovic S, Jankovic S, et al. CYP3A5 Polymorphism In Serbian Paediatric Epileptic Patients On Carbamazepine Treatment. *S J Exp and Clin Res*. 2015; 16(2):93–99.
61. Yun W, Zhang F, Hu C, Luo X, Xue P, Wang J, et al. Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. *Epilepsy Res*. 2013; 107(3):231–237. doi: [10.1016/j.eplepsyres.2013.09.011](#) PMID: [24125961](#)
62. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. *Lancet*. 1997; 350:630–633. PMID: [9288046](#)
63. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. *Arch Biochem Biophys*. 1997; 337:275–283. PMID: [9016823](#)
64. Kitteringham NR, Davis C, Howard N, Pirmohamed M, Park BK. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10,11-epoxide and naphthalene. *J Pharmacol Exp Ther*. 1996; 278:1018–1027. PMID: [8819481](#)
65. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. *Hum Mol Genet*. 1994; 3:421–428. PMID: [7516776](#)
66. Maekawa K, Itoda M, Hanioka N, Saito Y, Murayama N, Nakajima O, et al. Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects. *Xenobiotica*. 2003; 33:277–287. PMID: [12637245](#)
67. Nakajima Y, Saito Y, Shiseki K, Fukushima-Uesaka H, Hasegawa R, Ozawa S, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. *Eur J Clin Pharmacol*. 2005; 61:25–34. PMID: [15692831](#)
68. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. *Carcinogenesis*. 2002; 23(11):1839–1849. PMID: [12419832](#)
69. Bourgeois BF, Wad N. Carbamazepine-10, 11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. *Ther Drug Monit*. 1984; 6(3):259–265. PMID: [6506133](#)
70. Thompson CH, Kahlig KM, George AL. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. *Epilepsia*. 2011; 52(5):1000–1009. doi: [10.1111/j.1528-1167.2011.03040.x](#) PMID: [21453355](#)
71. Remy S, Gabriel S, Urban BW, Dietrich D, Lehmann TN, Elger CE, et al. A novel mechanism underlying drug resistance in chronic epilepsy. *Ann Neurol*. 2003; 53(4): 469–479. PMID: [12666114](#)

72. Ghosh C, Marchi N, Hossain M, Rasmussen P, Alexopoulos AV, Gonzalez-Martinez J, et al. A pro-convulsive carbamazepine metabolite: quinolinic acid in drug resistant epileptic human brain. *Neurobiol Dis.* 2012; 46(3):692–700.
73. Oby E, Caccia S, Vezzani A, Moeddel G, Hallene K, Guiso G, et al. In vitro responsiveness of human drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. *Brain Res.* 2006; 1086(1):201–213. PMID: [16631625](#)
74. Jandová K, Päsler D, Antonio LL, Raue C, Ji S, Njunting M, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. *Brain.* 2006; 129(12):3290–3306.